For adults with Chronic Idiopathic
Constipation (CIC)

Once-daily dosing.
Anytime with or without food.

Motegrity is a selective serotonin type 4 (5-HT4) receptor agonist.

Actor Portrayal

Motegrity (prucalopride) Dosing and Administration

Offers simple dosing to work with your patients’ schedules.1

Dosing icon

Once-daily dosing

Wrist watch

Any time of the day

Fork, spoon and knife

With or without food

It is important for patients to understand that Motegrity must be taken once daily as prescribed.1

Interested in receiving samples of Motegrity?

Your patients can benefit from a trial. Order a 7-day sample to get started.

package
Request Samples

Two dosage strengths

2 mg dose

2 mg

  • Recommended once daily adult Chronic Idiopathic Constipation (CIC) dosage1

1 mg dose

1 mg

  • Recommended once daily dosage for patients with Chronic Idiopathic Constipation (CIC) with severe renal impairment (creatinine clearance <30 mL‍/‍min)1
  • Avoid Motegrity in patients with end-stage renal disease requiring dialysis1

Motegrity® (prucalopride) bottle

Advise patients to:

  • Store Motegrity at 68°F to 77°F; with excursions permitted between 59°F to 86°F1
  • Store Motegrity in the original container to protect from moisture1
Bottle icon

Request Samples

Interested in receiving
samples of Motegrity?

Request samples
Map icon

Formulary Coverage

Wondering which plans in your area cover Motegrity? See our patient access coverage tool to find out more.

Patient access coverage tool

IMPORTANT SAFETY INFORMATION

Expand Collapse

Please expand for Indication and Important Safety Information.

Contraindications

  • Hypersensitivity to Motegrity. Reactions including dyspnea, rash, pruritus, urticaria, and facial edema have been observed
  • Intestinal perforation or obstruction due to structural or functional disorder of the gut wall, obstructive ileus, severe inflammatory conditions of the intestinal tract such as Crohn's disease, ulcerative colitis, and toxic megacolon/megarectum

Warnings and Precautions

Suicidal Ideation and Behavior: In clinical trials, suicides, suicide attempts and suicidal ideation have been reported. Postmarketing cases of suicidal ideation and behavior as well as self-injurious ideation and new onset or worsening of depression have been reported within the first few weeks of starting Motegrity. A causal association between treatment with Motegrity and an increased risk of suicidal ideation and behavior has not been established. Monitor patients for new onset or worsening of depression and emergence of suicidal thoughts and behavior. Instruct patients to discontinue Motegrity immediately and contact their healthcare provider if they experience any of these symptoms.

Adverse Reactions

Most common adverse reactions (≥2%) are headache, abdominal pain, nausea, diarrhea, abdominal distension, dizziness, vomiting, flatulence, and fatigue.

Use in Specific Populations

  • Lactation: Motegrity is present in breast milk. Consider risks and benefits of breastfeeding
  • Pediatric: Safety and effectiveness in pediatric patients have not been established
  • Renal Impairment: A decreased dosage is recommended in patients with severe renal impairment. Avoid Motegrity in patients with end-stage renal disease requiring dialysis

INDICATION

Motegrity® (prucalopride) is a serotonin-4 (5-HT4) receptor agonist indicated for the treatment of chronic idiopathic constipation (CIC) in adults.

Please click here for full Prescribing Information.

Reference:

1. Motegrity (prucalopride) Prescribing Information. Lexington, MA: Takeda Pharmaceuticals America, Inc.

©2024 Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA 02421. All rights reserved. 1-877-TAKEDA-7 (1-877-825-3327). MOTEGRITY® and the MOTEGRITY Logo® are registered trademarks of Takeda Pharmaceuticals U.S.A., Inc. TAKEDA and the TAKEDA logo are registered trademarks of Takeda Pharmaceutical Company Limited. US-PRU-0728v2.0 03/24.

All content of this website, including text, images, graphics, sound files, and their arrangement, is copyrighted and owned by Takeda and is protected by international copyright laws. All other intellectual property rights are reserved. The content may not be copied for commercial use or distribution, nor may these objects be downloaded, modified, or posted to other sites. This site is intended solely for US residents and is governed solely by US laws and government regulations. Please see our Legal Notice for more information. While Takeda makes reasonable efforts to include accurate, up-to-date information on this site, Takeda makes no warranties or representations as to its accuracy. Takeda assumes no liability for any errors or omissions in the content of this site. The information on this site is not intended to make a diagnosis or to take the place of talking to a US health care professional.